1. Pfizer (Sponsor) None known WC500046600_EMEA found at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000546/WC500046600.pdf
2. Pfizer (Sponsor) None known WC500046600_EMEA found at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000546/WC500046600.pdfWC500046600_EMEA
3. Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials;Freeman;Journal of Pain Research,2015
4. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?;Hoffman;Pain,2010
5. NCT00156078 A 14-week, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of pregabalin (150 mg-600 mg/day) using a flexible optimal dose schedule in patients with painful diabetic peripheral neuropathy (DPN) www.clinicaltrials.gov/ct2/show/NCT00156078